return equiti ttm
first-quart result clear revenu hurdl attent turn
week analyst day target
summari take-away
thursday may report first-quart result line organ
constant-curr revenu expect beat estim bottom line
back favor fx solid contribut neotract vsi lower tax time
oper expens spend view big beat kind quarterli result
start year compani need post bit shaki fourth quarter
fact believ especi import order requir credibl
offer long-term financi target next week compani analyst day new york
want ep revis given upsid quarter remind
investor first quarter year believ make sens let thing
develop bit year rais bar
stock maintain outperform rate base view long-term
revenu growth expect midsingle-digit slightli higher given neotract
contribut along basi point oper margin expans
yield ep number around repres midteen
earn compound-annual-growth-rate accret deal consumm aggress debt paydown
occur maximum benefit today announc restructur thu
stock trade time ep target view margin
expans stori opportun inorgan accret next coupl year
scarciti devic asset cap rang keep attract name
specif revenu came million report fxn
foreign currenc neutral basi beat target million wb million
consensu million given heavi fx upsid import metric
organ constant-curr growth adjust sell day
adjust believ street bogey
heavili debat last coupl month
term contribut vascular solut contribut basi point turn
organ midway quarter neotract ad basi point
assum organ adjust ship day exit surgic
product basi point organ growth would approxim use
similar logic organ growth would fourth quarter number
believ best repres growth compani capabl put
diversifi provid primarili single-us medic devic use treatment acut life-
threaten ill compani segment includ vascular access surgic anesthesia/respiratori
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
profit side gross margin improv year-over-year line target
oper margin line well manag point oper expens lower intern
expect due time certain invest spend around salesforc expans interest expens came
million better model compani paid tax rate well guidanc
coupl sizabl tailwind fx result adjust ep beat versu estim versu
addit result manag took opportun updat guidanc back favor fx environ
slightli lower tax rate assumpt compani rais report revenu growth target basi point
billion midpoint importantli compani adjust constant-curr growth expect
year adjust ep call midpoint though may
hope bit rais consid beat quarter support manag plan spend
upsid area pipelin develop repla neotract commerci infrastructur geograph expans
spend fx benefit consist among peer someth gener support addit never seem
make sens rais estim first quarter year
quarter meet bar set street set turn next friday analyst day hear
compani revenu margin target discuss adjust organ constant-curr revenu growth
trend rang last quarter prior manag commentari suggest revenu build
somewher rang well said vsi neotract get bigger expect slow
growth result believ street expect revenu growth somewher rang
oper margin compani roughli halfway previous announc restructur million-
million left ad cushion restructur announc today result pre-tax save million-
million end believ investor set bar rang cours time bill
come due target would expect look differ today remain portion
strategi
addit commentari highlight call
 distribut headwind fourth quarter appear mostli bounc back fourth quarter
manag estim million north american shortfal million total due major
distribut partner work inventori respiratori anesthesia product expect come
back throughout first half year first quarter manag estim roughli million fact
come back though remain bit perplex behind dynam actual caus distributor work
inventori strongest respiratori season last decad suspect issu larg behind
compani lion share came back quarter remain bit still need realiz
suspect occur quarter
addit invest help revenu growth object sacrif bottom line due
favor fx environ tax benefit manag announc plan use benefit
fund repla clinic trial addit neotract initi asia repla compani freeze-
dri plasma product develop initi militari applic follow compani second meet
fda depart defens april manag confid opportun bring product
market acceler fashion increas spend pave way bla submiss
like earli
regard neotract spend previou guidanc contempl addit sale rep clinic
reimburs personnel strength far opportun expand asia-pacif market
japan australia china singapor taiwan compani felt time add increment peopl
plan though know magnitud job function add market massiv
under-penetrated believ put asset toward product make lot financi strateg sens
footprint realign provid addit cushion long-term stori addit first-
quarter result manag outlin new restructur plan expect substanti complet
end reduct current announc employe specif detail wrap
believ major estim million annual pre-tax save
realiz follow previou restructur effort help juic oper margin expans
basi point last five year
quarter reviewcurr actualcurr estimateprior year quarter thousand unless revenu revenu estim driven larg fx tailwind estim fx revenu beat estim report basi organ total revenu fxn day adjust growth line street expect us distributor re-stock shortfal come backgross note surgic na fxn estim bp bp larg due plan exit certain product line well focu oper promot higher gm product surgic oper bp income/ expens nmprofit margin expect earn gm line estim benefit high neotract gmincom tax op margin also came larg expect though manag note effect bp spend occur due time spend like incom nci- occur throughout rest year net incom bp dilut share ep consensu estim currentrevenu earn per sourc william blair compani estim compani report factset consensusfav/ unfav variancey/i chang william blair
model chang thousand unless notedprevi estimatechangecurr guidanceiniti estimatecommentarytot revenu revenu estim increas due fx fx revenu target increas due atot revenu favor fx environ guid call tailwindcost neotract forecast produc revenu thegross year in-lin mgm commentari least bp organ growth model higher-end theoper guidanc rangeoper bp profit ep adjust fx taxoth income/ expens margin remain rel unchang line guidanceearn oper margin expans fast due neotract sincom lower overal op margin corpor averag despit effect tax bp underli margin expans remain intact suspectincom nci long-term target achiev net incom tax guid low end rang bp share ep sourc william blair compani estim compani reportsconsensu estim revenu earn per sourc import disclosur
